B. Braun set to launch recently FDA-cleared xevonta in U.S. this month

B. Braun Medical said it will begin making its xevonta kidney dialyzer available in the U.S. this month, following the recent 501(k) clearance by the FDA.

Often referred to as an “artificial kidney,” the dialyzer is a dialysis filter that removes wastes and excess fluid from the blood when a patient's kidneys can no longer perform the task, the company said. The enhanced xevonta system can filter out smaller toxin molecules in a patient's blood, like urea and creatinine, while keeping most of the larger blood components, like albumin and beta-2 microglobulin molecules, that are vital to a patient's health.

The device will be available in a range of sizes to meet various patient needs.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"Our new dialyzer's advanced membrane technology was designed to improve clearance performance by removing more toxins from a patient's blood," Samuel Amory, vice president of the company’s renal therapies division, said in a statement.

B. Braun manufactures and distributes hemodialysis equipment and related disposables, including the Diacap Polysulfone dialyzers and Medisystems' Streamline Bloodlines.

Back in May, the company was slapped by the FDA with a Class I recall--the agency’s most serious--of more than 1,000 of its Dialog+ Hemodialysis Systems used to treat chronic kidney disease patients. The devices had the potential of allowing air to enter the dialysis solution, which could lead to improper blood filtration as well as other consequences including death.


Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.